Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and do not yet have commercially available drugs or therapeutics. That status also means negative earnings and little to no revenue. Success often depends on the outcome of a single clinical-stage drug or therapeutic. Legendary former hedge fund manager Larry Benedict built his reputation by delivering clarity in the markets when others were overwhelmed by noise. That's exactly what makes today's message so important: on this final "end of the year" deadline, Larry is laying out everything you can access for just $19. Learn this time-tested strategy today Even when a product advances through trials, profitability can remain years away. Only after reaching commercial milestones do companies typically attract analyst coverage and the institutional investment that follows. That said, getting in on one of these medical stocks before it succeeds can be like winning the lottery: returns of 3x, 5x, or even 10x are possible. Many other names will never pan out, which is why investors who pursue penny stocks often spread a lump sum across multiple biotech companies. If it’s a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in the space, Mainz Biomed already has a commercial product: ColoAlert, the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading German digital health company. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also developing a non-invasive blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. However, commercial approval for that program remains years away. The risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. The company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering. For now, that offering helps keep the MYNZ stock price above $1 and avoids a delisting notice. Mainz Biomed must generate meaningful revenue to change its financial outlook. If it succeeds, even a modest investment today could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive approach to antiviral treatment—but it carries the financial risks investors should weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces, luring viruses to bind with them and neutralizing the pathogens before they can infect real cells. It’s an innovative approach that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical activity. Like many micro-cap biotechs, NanoViricides is pre-revenue and dependent on fresh capital to advance its programs. Recent filings show limited cash on hand, so investors should anticipate the possibility of future dilution. Still, if one candidate advances successfully into clinical trials, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
